Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
BURLINGTON, ON and TORONTO, Jan. 23, 2024 /CNW/ - Health Canada has authorized Jardiance® (empagliflozin) to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular and ...
BURLINGTON, ON, Oct. 11, 2023 /CNW/ - Boehringer Ingelheim (Canada) Ltd. and BI X, the digital lab of Boehringer Ingelheim, have collaborated to introduce a new digital clinical support tool for...
- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated...
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice1,2,3 Phase III trial also...
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for...
BURLINGTON, ON, May 3, 2022 /CNW/ - Boehringer Ingelheim (Canada) Ltd. is pleased to announce that OFEV® (nintedanib), is now available for public reimbursement in Quebec, Ontario, Alberta, New...
The project will use artificial intelligence (A.I.), wearable technologies and electronic health record systems to identify patients who may have type 2 diabetes in Montreal, Quebec MONTREAL, April...
JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure...
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases...
This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25 per cent reduction in the combined relative risk versus placebo of cardiovascular death or hospitalization for ...
There's no time to wait when it comes to supporting those living with Pulmonary Fibrosis BURLINGTON, ON, Sept. 20, 2021 /CNW/ - September is Pulmonary Fibrosis (PF) Awareness Month, a time to raise...
Results from the Phase III EMPEROR-Preserved trial were presented August 27 at the European Society of Cardiology Congress 20211 and published in The New England Journal of Medicine2 In this clinical ...
Aservo™ EquiHaler™ (ciclesonide inhalation solution) leverages synergies between the company's human pharma and animal health divisions to set new standards of care. An industry first in equine...
OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than...
BURLINGTON, ON, Oct. 7, 2020 /CNW/ - Indigenous communities burdened with up to three times the national rates of chronic diseases now have access to an innovative health project fund established by...
Industry-first partnership between Pallium Canada and Boehringer Ingelheim Canada aims to expand access to palliative care, even as pandemic creates new challenges BURLINGTON, ON, Sept. 18, 2020...
Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart failure by 30 per cent and significantly slowed kidney function decline1 Results were...
Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with...
NexGard® and NexGard Spectra™ receives Health Canada approval for the reduction of Borrelia burgdorferi (B. burgdorferi) infections as a direct result of killing adult Ixodes scapularis (I....
OFEV® is the first treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)2 It...
Continuum is a large-scale project developed by a partnership of CRCHUM, Greybox Solutions Inc., MEDTEQ and Boehringer Ingelheim Canada MONTREAL, Dec. 9, 2019 /CNW/ - Montreal's innovation...
BURLINGTON, ON, Nov. 27, 2019 /CNW/ - Boehringer Ingelheim (Canada) Ltd. announced today that Health Canada has approved OFEV® (nintedanib) as the first and only treatment indicated to slow the rate...
BURLINGTON, ON, Oct. 9, 2019 /CNW/ - Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function decline by 57% across the overall study population, as...
VANCOUVER, June 11, 2019 /CNW/ - The University of British Columbia (UBC) is launching Canada's first blockchain and distributed ledger technology training path for graduate students. The initiative...
Blockchain technology has the potential to improve trust, transparency, patient safety and patient empowerment in clinical trials BURLINGTON, ON and MARKHAM, ON, Feb. 12, 2019 /CNW/ - Boehringer...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.